Trial · NCT00607113

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

NCT00607113, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2013-05-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma. Trials, record NCT00607113. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00607113

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
NCT number: NCT00607113
Status: Completed
Phases: Phase 2
Enrollment: 41 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Neuroendocrine Carcinoma
Interventions: Avastin, RAD001
First posted: 2008-02-05
Last updated: 2013-07-18
Results first posted: 2013-05-08

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Net Change Relative to Baseline in Tumor Blood Flow	Baseline to end of Cycle 3 (63 days)	Tumor blood flow (ml/min/100gm) determined by functional computed tomography (CT). Functional computed tomography (CT) at baseline, after first and third cycles (21 day cycles). Change (percentage) calculated as tumor blood flow measured at baseline compared to tumor blood flow measurement taken at end of Cycle 1, week 3 (21 days), and again at end of Cycle 3, Week 9 (63 days).

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Net Change Relative to Baseline in Tumor Blood Flow	Baseline to end of Cycle 3 (63 days)		ml/min/100gm	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Net Change Relative to Baseline in Tumor Blood Flow	Avastin	Baseline to Week 3	-0.44	Standard Deviation 0.32	ml/min/100gm
Net Change Relative to Baseline in Tumor Blood Flow	RAD001	Baseline to Week 3	-0.12	Standard Deviation 08.16	ml/min/100gm
Net Change Relative to Baseline in Tumor Blood Flow	Avastin	Baseline to Week 9	-0.60	Standard Deviation 0.44	ml/min/100gm
Net Change Relative to Baseline in Tumor Blood Flow	RAD001	Baseline to Week 9	-0.40	Standard Deviation 0.27	ml/min/100gm

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Avastin	19
Overall Study	STARTED	RAD001	20
Overall Study	COMPLETED	Avastin	19
Overall Study	COMPLETED	RAD001	20
Overall Study	NOT COMPLETED	Avastin	0
Overall Study	NOT COMPLETED	RAD001	0

Source ClinicalTrials.gov

Adverse events44

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	ALT ELEVATION	Metabolism and nutrition disorders	Avastin + RAD001	5	39
other	ANEMIA	Blood and lymphatic system disorders	Avastin + RAD001	13	39
other	ANOREXIA	Gastrointestinal disorders	Avastin + RAD001	14	39
other	AST ELEVATION	Metabolism and nutrition disorders	Avastin + RAD001	6	39
other	COUGH	Respiratory, thoracic and mediastinal disorders	Avastin + RAD001	7	39
other	DIARRHEA	Gastrointestinal disorders	Avastin + RAD001	19	39
other	DIZZINESS	General disorders	Avastin + RAD001	7	39
other	DYSGEUSIA	Nervous system disorders	Avastin + RAD001	5	39
other	DYSPNEA	Respiratory, thoracic and mediastinal disorders	Avastin + RAD001	9	39
other	EDEMA	General disorders	Avastin + RAD001	18	39

1 to 10 of 44Source ClinicalTrials.gov

See all 44 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Avastin + RAD001
Total, other adverse events	Avastin + RAD001	39	39
Total, serious adverse events	Avastin + RAD001	35	39

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
25426617	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00607113

GET https://conductscience.org/api/trials/v1/NCT00607113/events?page=2

API reference For AI assistants